Genomic and clinical predictors of cardiovascular disease in Familial dyslipidemia: risk stratification in Egyptian adolescents and young adults
Authors:
- Ammal M. MetwallyAMAmmal M. Metwally
- Nesma M. ElarabyNENesma M. Elaraby
- Wafaa M. EzzatWEWafaa M. Ezzat
- Mark O. DimitryMDMark O. Dimitry
- Ghada A. ElshaarawyGEGhada A. Elshaarawy
- Neveen A. AshaatNANeveen A. Ashaat
- Ashraf RedaARAshraf Reda
- Ahmed BendaryABAhmed Bendary
- Mohamed H. AbbasMAMohamed H. Abbas
- Tarek R. El MawardyTMTarek R. El Mawardy
- Walaa A. BashaWBWalaa A. Basha
- Iman H. KamelIKIman H. Kamel
Open Access
- 15 December 2025
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Abstract
Familial dyslipidemia (FD), particularly familial hypercholesterolemia (FH), is a major contributor to premature cardiovascular disease (CVD), especially in regions with high consanguinity and underutilized genetic screening, such as Egypt. This study aimed to assess clinical, biochemical, and genetic factors that differentiate FD patients with and without CVD, and to develop a composite risk score for individualized stratification. A cross-sectional study was conducted on 60 Egyptian patients aged 15–25 years with genetically confirmed FD, equally divided based on CVD status. All participants underwent detailed clinical assessment, lipid profiling, and targeted next-generation sequencing of LDLR , APOB , and PCSK9 genes. Missense variants were evaluated using SIFT, PolyPhen-2, CADD, and ΔΔG stability scores, and classified according to ACMG criteria. Compared to non-CVD patients, those with CVD had significantly higher triglyceride levels (median: 356.5 vs. 236.5 mg/dL; p < 0.001) and a higher frequency of heterozygous pathogenic LDLR variants (30.0% vs. 3.3%; p = 0.006), while homozygous variants were more common in non-CVD patients (26.7% vs. 0%; p = 0.002). Deleterious missense variants were notably more frequent in the CVD group (56.7% vs. 10.0%; p < 0.001). A 10-variable composite risk score integrating clinical, lipid, and bioinformatic predictors effectively distinguished high- and moderate-risk cases (AUC = 0.742; p = 0.022), with 89.5% sensitivity and 81.8% negative predictive value. The study highlights the importance of combining clinical and genomic data for early risk stratification and introduces a pragmatic tool for identifying high-risk youth in resource-limited, consanguineous populations.Keywords
Funding Information
- National Research Centre Egypt
This publication has 111 references indexed in Scilit:
- The Diagnostic Value of Whole-Exome Sequencing in a Spectrum of Rare Neurological Disorders Associated with Cerebellar AtrophyMolecular Neurobiology, 2023
- Association between obesity categories with cardiovascular disease and its related risk factors in the MASHAD cohort study populationJournal of Clinical Laboratory Analysis, 2019
- Overview of Specifications to the ACMG/AMP Variant Interpretation GuidelinesCurrent Protocols in Human Genetics, 2019
- Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2Current Protocols in Human Genetics, 2013
- Endothelial dysfunction in rheumatic autoimmune diseasesAtherosclerosis, 2012
- Limited mutational heterogeneity in the LDLR gene in familial hypercholesterolemia in TunisiaAtherosclerosis, 2009
- Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.The American Journal of Cardiology, 2008
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondStatistics in Medicine, 2007
- Statistical Methods for Rates and Proportions2003
- Molecular genetics of the LDL receptor gene in familial hypercholesterolemiaHuman Mutation, 1992